-
Trevi Therapeutics NasdaqGM:TRVI Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF; phase 2 clinical trial in patients with pruritus; and phase 2b/3 clinical trial in patients with prurigo nodularis. Trevi Therapeutics, Inc. has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Location: 195 Church Street, New Haven, CT, 06510, United States | Website: https://www.trevitherapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
544.8M
Cash
103.3M
Avg Qtr Burn
-10.32M
Short % of Float
10.72%
Insider Ownership
15.68%
Institutional Own.
87.17%
Qtr Updated
03/31/25
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Haduvio (oral nalbuphine ER) Details Idiopathic pulmonary fibrosis Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 2b Data readout | |
Haduvio (oral nalbuphine ER) Copy Details Refractory Chronic Cough | Phase 2a Update |